-
Site License
-
Site License
-
Enterprisewide
-
Enterprisewide
Systemic Fungal Infection Therapeutics Market – India
Frost & Sullivan, November 2009, Pages: 43
This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in India.
This Frost & Sullivan research service titled Systemic Fungal Infection Therapeutics Market – India provides an analysis of the current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. This study is aimed at supporting manufacturers in decision making in identifying and prioritizing opportunities in India.
Market Overview
Advances in Diagnostic Tests Expand Possibilities for a More Targeted Approach to Treatment of Systemic Fungal Infections
With fast-paced advancements in technology, the number of patients diagnosed with systemic fungal infections (SFIs) is expected to increase steadily over the next five years. Alongside this development, a high premium on products that are capable of tackling emergent, problematic pathogens will also contribute to changing market dynamics. Estimates reveal that the global prevalence of SFI has risen to 4 for every 1,000 of the global population. The high incidence of SFI over the years is attributed to the widespread use of broad–spectrum antibiotics, which reduce non–pathogenic bacterial populations that compete with fungi, and the growing number of persons with compromised immune systems caused by acquired immunodeficiency syndrome (AIDS), immunosuppressant drugs, and chemotherapy agents. "Early diagnosis of systemic fungal infections has been shown to be critical to treatment outcome," notes the analyst of this research service. "Advances in diagnostic capabilities are paving the way for more increased usage of targeted therapy for systemic fungal infections; this is reflected in the growing proportion of patients treated definitively in the last five years."
Although key therapeutics have been in the market to treat the most causative pathogen (Candida Albicans), there is still an unmet need to treat more resistant pathogens such as Aspergillus. Despite the advent of more advanced molecular diagnostic technologies, physicians in India continue to use empiric and prophylactic therapies to treat SFI. As more resistant pathogens in systemic fungal infections emerge, treatment is centered on ensuring that the right treatment is administered to the patient. "Doctors are under pressure to ensure that they identify the most suitable mode of treatment, based on universal criteria, such as risk factors, clinical, radiological, microbiological or other diagnostic evidence," says the analyst. "The task is made easier for physicians with the growing availability of non-microbiologic and clinical diagnostic techniques, such as Platelia, Fungitell and PNA FISH, to identify the onset of infection." This places greater emphasis on matching antifungal choice to pathogen susceptibility, increasing the demand for rapid typing of pathogens to ensure informed, targeted drug choices. Consequently, there would be a reduction in the use of prophylaxis in the ‘at-risk’ patient group and the empiric therapy in, for example, patients in this group with a persistent fever or other suggestive symptoms.
Considering the relatively niche nature of SFI, it is vital for key participants to differentiate their products, especially as advances in diagnostic techniques bring about a restriction of prescriptions to specific therapeutic uses. Therapeutics are shifting away from broad and empiric indications, and pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and sub species) and patient populations, rather than a broad spectrum. This gives room for a higher degree of differentiation, protecting the specific drug from generic erosion in the future. The changing epidemiology of causative pathogens has caused the effectiveness of existing therapeutic options to decline. In such a scenario, pharmaceutical manufacturers need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups, that is, solid organ transplant, cancer, neonates, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), and surgical patients
1 | EXECUTIVE SUMMARY
- Overview
-- 1. India Executive Summary
2 | SYSTEMIC FUNGAL INFECTION THERAPEUTICS MARKET
- Market Overview
-- 1. Introduction
-- 2. Context for the Study
-- 3. Scope and Segmentation of the Study
-- 4. Methodology
-- 5. Restraints in Forecasts
3 | INDIAN SYSTEMIC FUNGAL INFECTION THERAPEUTICS MARKET
- Market Overview
-- 1. Introduction
-- 2. Measurements
-- 3. Government Initiatives
- SFI Patients
-- 1. Patient Source and Quantification
-- 2. Causative Pathogens
-- 3. Patient Forecasts
-- 4. Cost of Treatment
- Treatment and Diagnosis
-- 1. Key Treaters and Patient Flow
-- 2. Diagnostic Tests and Monitoring
-- 3. Treatment Options
-- 4. Treatment Patterns
-- 5. Product Share Analysis
-- 6. Product Launches
-- 7. Clinical Trials
- Competitive Analysis
-- 1. Competitive Structure
-- 2. Future Trends
-- 3. Challenges Faced by Physicians
4 | APPENDIX
- India
-- 1. Appendix-1
LIST OF FIGURES:
Chapter 3:
- Systemic Fungal Infection Therapeutics Market: Number of SFI Patients and Prevalence Rate (India), 2003-2012
- Systemic Fungal Infection Therapeutics Market: SFI Incidence (India), 2003-2012
- Systemic Fungal Infection Therapeutics Market: Patient Forecasts (India), 2003-2012
- Systemic Fungal Infection Therapeutics Market: Cost of Therapy per SFI Patient for Most Prescribed Drugs—Generic Fluconazole Oral and Vfend IV (India), 2003-2012
- Systemic Fungal Infection Therapeutics Market: Attributes that Influence Prescription Choice (India), 2008
- Systemic Fungal Infection Therapeutics Market: Average Daily Dosage and Days of Therapy in Prophylactic Treatment (India), 2008
- Systemic Fungal Infection Therapeutics Market: Average Daily Dosage and Days of Therapy in Empirical Treatment (India), 2008
- Systemic Fungal Infection Therapeutics Market: Average Daily Dosage and Days of Therapy in Definitive Treatment (India), 2008
- Systemic Fungal Infection Therapeutics Market: List of Clinical Trials Conducted by Phase, Patient Age, Stage, Drug, and Sponsor (India), 2008
- Systematic Fungal Infection Therapeutics Market: Competitive Structure (India), 2008
- Systematic Fungal Infection Therapeutics Market: Prescription Projection of Key Agents (India), 2008
Chapter 4:
- Systemic Fungal Infection Therapeutics Market: Total Population and Population Growth Rate (India), 2003-2012
- Systemic Fungal Infection Therapeutics Market: Assumptions for Patient Forecasts (India), 2008
- Systemic Fungal Infection Therapeutics Market: List of Prescribed First- and Second-line SFI Drugs (India), 2008
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
